Ocrevus®

Understanding Ocrevus® 

Ocrevus® (ocrelizumab) is a monoclonal antibody therapy used to treat multiple sclerosis (MS) by targeting CD20-positive B cells, which play a key role in the immune system’s attack on the nervous system in MS. By selectively depleting these B cells, Ocrevus® helps to reduce inflammation, slow disease progression, and improve overall outcomes for patients with MS.

How Ocrevus® Works:

• Targets and depletes CD20-positive B cells to reduce immune system attacks on the nervous system.
• Decreases inflammation and helps prevent further nerve damage.
• Slows disease progression and improves long-term outcomes in MS.

FDA Approval:

• Ocrevus® (ocrelizumab): Approved on March 28, 2017

For more information, please visit the Ocrevus® patient website and speak with your healthcare provider to determine if Ocrevus® is the right treatment option for you.